Overall and cancer specific survival following radical or adjuvant (chemo)radiotherapy in a retrospective cohort of elderly patients with endometrial cancer

To report the overall survival and cancer specific survival outcomes of elderly women aged ≥70 years who received radical or adjuvant (chemo)radiotherapy for endometrial cancer, we conducted a retrospective review of 93 patients from the West of Scotland Cancer Network (WoSCAN) who received pelvic (+/− para-aortic) radiotherapy over a 5-year period (January 2011 to December 2015, inclusive). Association of treatment type and other variables with overall survival (OS) and cancer specific survival (CSS) were analysed using log rank tests and Cox proportional hazards models. Median age of the study population was 74 years (range 70–90 years); over 50% of patients were aged ≥75 years, and over 25% were ≥80 years. The majority of patients had endometrioid endometrial cancer (75.3%), and 24.7% had a high-risk histological subtype. Stage distribution was as follows: I/II (40.9%); III/IV (41.9%); recurrent disease (17.2%). Radiotherapy was predominantly delivered in the adjuvant setting (61.3%); intent was primary (22.6%) or salvage (16.1%) in the remaining patients. Chemotherapy was administered to almost 50% of the cohort, mainly in conjunction with adjuvant radiotherapy. After median follow up of 96 months, 5-year OS and CSS were 50.5%and CSS 59.3% for the entire series, 57.9% and 62.8% in the adjuvant group, 23.8% and 35.7% in the primary group, and 60.0% and 80.0% in the salvage group, respectively. Age ≥80 years and primary radiotherapy were statistically significant predictors of poorer survival, adjusting for pathology, stage and grade (hazard ratio (HR) 2.06, 95%Confidence Interval (CI) (1.11–3.80), p = 0.021; and HR 2.42 (CI 1.28–4.57), p = 0.006 respectively). In summary, poorer OS was associated with use of (chemo)radiotherapy as primary treatment of endometrial cancer and/or in women aged ≥80 years, suggesting that careful risk/benefit analysis is required in these two groups.

Endometrial cancer; Elderly; Radiotherapy; Chemotherapy; Chemoradiotherapy; Real-world; Surgery

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Eggemann H, Ignatov T, Burger E, Costa SD, Ignatov A. Management of elderly women with endometrial cancer. Gynecologic Oncology. 2017; 146: 519–524.

[3] Torgeson A, Boothe D, Poppe MM, Suneja G, Gaffney DK. Disparities in care for elderly women with endometrial cancer adversely effects survival. Gynecologic Oncology. 2017; 147: 320–328.

[4] Rousselin A, Bendifallah S, Nyangoh Timoh K, Ouldamer L, Canlorbe G, Raimond E, et al. Patterns of care and the survival of elderly patients with high-risk endometrial cancer: a case-control study from the FRANCOGYN group. European Journal of Surgical Oncology. 2017; 43: 2135–2142.

[5] Benito V, Lubrano A, Andújar M, Mori M, Federico M. Management of endometrial cancer in patients aged 80 years and older: identifying patients who may benefit from a curative treatment. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2019; 242: 36–42.

[6] Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer. 2021; 31: 12–39.

[7] de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology. 2018; 19: 295–309.

[8] de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. The Lancet Oncology. 2019; 20: 1273–1285.

[9] Dutta SW, Trifiletti DM, Grover S, Boimel P, Showalter TN. Man-agement of elderly patients with early-stage medically inoperable endometrial cancer: systematic review and national cancer database analysis. Brachytherapy. 2017; 16: 526–533.

[10] Gannavarapu BS, Hrycushko B, Jia X, Albuquerque K. Upfront radio-therapy with brachytherapy for medically inoperable and unresectable patients with high-risk endometrial cancer. Brachytherapy. 2020; 19: 139–145.

[11] Weitmann HD, Pötter R, Waldhäusl C, Nechvile E, Kirisits C, Knocke TH. Pilot study in the treatment of endometrial carcinoma with 3D image-based high-dose-rate brachytherapy using modified Heyman packing: clinical experience and dose-volume histogram analysis. International Journal of Radiation Oncology, Biology, Physics. 2005; 62: 468–478.

[12] Yaney A, Healy E, Wald P, Olsen M, Pan X, Martin D, et al. Toxicity and outcomes associated with high-dose rate brachytherapy for medically inoperable endometrial cancer. Brachytherapy. 2021; 20: 368–375.

[13] Inciura A, Atkocius V, Juozaityte E, Vaitkiene D. Long-term results of high-dose-rate brachytherapy and external-beam radiotherapy in the primary treatment of endometrial cancer. Journal of Radiation Research. 2010; 51: 675–681.

[14] Kucera H, Knocke T, Kucera E, Pötter R. Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstetricia Et Gynecologica Scandinavica. 1998; 77: 1008–1012.

[15] Espenel S, Kissel M, Garcia MA, Schernberg A, Gouy S, Bockel S, et al. Implementation of image-guided brachytherapy as part of non-surgical treatment in inoperable endometrial cancer patients. Gynecologic Oncology. 2020; 158: 323–330.

[16] Wegner RE, Heron DE, Kim H, Mogus R, Beriwal S. Definitive radiation therapy for endometrial cancer in medically-inoperable elderly patients. Brachytherapy. 2009; 8: 142–143.

[17] van der Steen-Banasik E, Christiaens M, Shash E, Coens C, Casado A, Herrera FG, et al. Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma. European Journal of Cancer. 2016; 65: 172–181.

[18] Sapienza LG, Ning MS, de la Pena R, McNew LK, Jhingran A, Georgeon L, et al. Outcomes and toxicity after salvage radiotherapy for vaginal relapse of endometrial cancer. International Journal of Gynecologic Cancer. 2020; 30: 1535–1541.

[19] Chapman CH, Maghsoudi K, Littell RD, Chen L, Hsu I. Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy. Brachytherapy. 2017; 16: 1152–1158.

[20] Arden JD, Gruner MF, Vu CC, Marvin K, Ye H, Nandalur SR, et al. Outcomes after salvage radiation therapy for recurrent endometrial cancer in patients with no prior adjuvant therapy: an institutional review. Advances in Radiation Oncology. 2020; 5: 1240–1247.

[21] Schwarz JK, Beriwal S, Esthappan J, Erickson B, Feltmate C, Fyles A, et al. Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. Brachytherapy. 2015; 14: 587–599.

[22] Arians N, Oelmann-Avendano JT, Schmitt D, Meixner E, Wark A, Hoerner-Rieber J, et al. Evaluation of uterine brachytherapy as primary treatment option for elderly patients with medically inoperable endometrial cancer-a single-center experience and review of the literature. Cancers. 2020; 12: 2301.

[23] Duska L, Shahrokni A, Powell M. Treatment of older women with endometrial cancer: improving outcomes with personalized care. American Society of Clinical Oncology Educational Book. 2016; 123: 164–174.

[24] Falandry C, Weber B, Savoye AM, Tinquaut F, Tredan O, Sevin E, et al. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Annals of Oncology. 2013; 24: 2808–2813.

[25] Dankulchai P, Petsuksiri J, Chansilpa Y, Hoskin PJ. Image-guided high-dose-rate brachytherapy in inoperable endometrial cancer. The British Journal of Radiology. 2014; 87: 20140018.

[26] Schwarz JK, Beriwal S, Esthappan J, Erickson B, Feltmate C, Fyles A, et al. Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. Brachytherapy. 2015; 14: 587–599.

[27] Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. The New England Journal of Medicine. 1999; 340: 1144–1153.

[28] León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. Journal of Clinical Oncology. 2020; 38: 3388–3397.

[29] Alexa M, Hasenburg A, and Battista MJ. The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. Cancers. 2021; 13: 1478.

[30] Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.